The clinical outcomes of high neutralizing antibodies titer convalescent plasma therapy in early developed severe COVID-19 patients; a case–control study

BACKGROUND: Coronavirus disease 2019 (COVID-19) causes life-threatening pneumonia. Convalescent plasma therapy (CPT) is expected to be the effective COVID-19 treatment for passive immunity. The high neutralizing antibodies titer of CPT is needed to prove the benefit in early developed severe COVID-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Nontawong, Nuttakant, Siripongboonsitti, Taweegrit, Tawinprai, Kriangkrai, Boonpratoom, Mana, Krailassiri, Nawin, Boonkhum, Chayaporn, Soonklang, Kamonwan, Poovorawan, Yong, Mahanonda, Nithi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675119/
https://www.ncbi.nlm.nih.gov/pubmed/36403020
http://dx.doi.org/10.1186/s12941-022-00542-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675119/
https://www.ncbi.nlm.nih.gov/pubmed/36403020
http://dx.doi.org/10.1186/s12941-022-00542-2

Ejemplares similares